Drug intelligence / Profile preview

clortermine

Development stage
Discontinued
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

Clortermine is an anorectic drug of the amphetamine class, developed by Ciba in the 1960s for short-term adjunctive treatment of exogenous obesity. It is a sympathomimetic amine and a structural analogue of phentermine, specifically the 2-chloro analogue. Unlike typical amphetamines, clortermine produces very low rates of self-administration in animals and likely does not act primarily on dopamine pathways. Instead, it may function as a serotonin and/or norepinephrine releasing agent to suppress appetite. Its long duration allows for once-daily dosing. Common side effects include insomnia, dry mouth, palpitations, and tachycardia[3][4][6][8].

Brand names
Voranil
Other names
clortermine hydrochlorideClortermina1-(2-chlorophenyl)-2-methylpropan-2-amine2-chloro-alpha,alpha-dimethylphenethylamine2-chloro-alpha-methylamphetamine2-chlorophentermine
02

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on clortermine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clortermine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call